Prism Medico & Pharmacy Ltd is Rated Sell

Current Rating and Its Significance

MarketsMOJO’s 'Sell' rating for Prism Medico & Pharmacy Ltd indicates a cautious stance towards the stock, suggesting that investors should consider reducing exposure or avoiding new purchases at this time. This rating is based on a comprehensive evaluation of the company’s quality, valuation, financial trend, and technical indicators. The rating was last revised on 18 Nov 2025, when the Mojo Score dropped from 53 (Hold) to 37 (Sell), reflecting a significant reassessment of the stock’s prospects.

Here’s How the Stock Looks Today

As of 17 July 2026, Prism Medico & Pharmacy Ltd remains a microcap company operating within the Non Banking Financial Company (NBFC) sector. The latest data shows a mixed performance across various parameters, which collectively justify the current 'Sell' rating.

Quality Assessment

The company’s quality grade is below average, signalling underlying operational challenges. Prism Medico & Pharmacy Ltd continues to report operating losses, which undermines its long-term fundamental strength. Its ability to service debt is notably weak, with an average EBIT to interest ratio of -0.06, indicating that earnings before interest and taxes are insufficient to cover interest expenses. Furthermore, the average Return on Equity (ROE) stands at a modest 0.59%, reflecting low profitability relative to shareholders’ funds. These factors highlight concerns about the company’s operational efficiency and financial health.

Valuation Considerations

Valuation metrics paint a challenging picture for investors. The stock is graded as very expensive, trading at a Price to Book Value (P/B) ratio of 2.6, which is a premium compared to its peers’ historical averages. Despite this high valuation, the company’s ROE is only 2.2%, suggesting that investors are paying a significant premium for relatively low returns. While the stock has delivered a remarkable 106.21% return over the past year, this price appreciation appears disconnected from the underlying profitability, which has increased by 38% during the same period. The resulting Price/Earnings to Growth (PEG) ratio of 0.3 indicates that the market is pricing in growth expectations that may be optimistic given the company’s fundamentals.

Financial Trend Analysis

The financial trend for Prism Medico & Pharmacy Ltd is flat, with recent quarterly results showing limited improvement. The March 2026 quarter recorded the lowest figures in key profitability metrics: PBDIT (Profit Before Depreciation, Interest and Taxes) at a loss of ₹0.13 crore, PBT (Profit Before Tax) less other income at a loss of ₹0.12 crore, and Earnings Per Share (EPS) at a negative ₹0.40. These results underscore the company’s ongoing struggles to generate consistent profits and improve its financial trajectory.

Technical Outlook

Technically, the stock exhibits a mildly bullish trend, with short-term price movements showing some positive momentum. Over the last six months, the stock has gained 61.01%, and year-to-date returns stand at 53.89%. The one-month return is also positive at 8.86%, despite a slight dip of 4.63% over three months. The daily change as of 17 July 2026 is a modest +0.03%. While these technical indicators suggest some investor interest and buying activity, they are not sufficient to offset the concerns raised by the company’s fundamental and valuation metrics.

Implications for Investors

For investors, the 'Sell' rating serves as a cautionary signal. The combination of weak operational quality, expensive valuation, flat financial trends, and only mild technical strength suggests that the stock may face headwinds in sustaining its recent price gains. Investors should carefully weigh the risks associated with the company’s financial health and valuation premium before considering any new investment or holding existing positions.

Summary of Key Metrics as of 17 July 2026

To summarise, the stock’s key performance indicators as of today include:

• Mojo Score: 37.0 (Sell grade)
• Market Capitalisation: Microcap segment
• Operating Losses with weak EBIT to Interest ratio (-0.06)
• Return on Equity: 0.59% average, 2.2% latest
• Price to Book Value: 2.6, indicating expensive valuation
• Stock Returns: 1 Year +106.21%, 6 Months +61.01%, YTD +53.89%
• Quarterly EPS: Negative ₹0.40

Understanding the Rating in Context

The 'Sell' rating from MarketsMOJO reflects a holistic view of Prism Medico & Pharmacy Ltd’s current investment appeal. While the stock has delivered strong price returns recently, the underlying fundamentals and valuation metrics suggest caution. The rating advises investors to critically assess the sustainability of the company’s growth and profitability before committing capital. This approach helps investors avoid potential downside risks associated with overvalued stocks that lack robust financial health.

Sector and Market Position

Operating within the NBFC sector, Prism Medico & Pharmacy Ltd faces competitive pressures and regulatory challenges typical of this space. Its microcap status further adds to liquidity and volatility considerations. Investors should compare this stock’s profile with other NBFC peers to gauge relative value and risk. The current valuation premium, despite modest profitability, suggests that market expectations may be optimistic relative to sector fundamentals.

Conclusion

In conclusion, Prism Medico & Pharmacy Ltd’s 'Sell' rating as of 18 Nov 2025 remains justified based on the company’s current financial and market position as of 17 July 2026. Investors are advised to approach this stock with caution, recognising the risks posed by weak quality metrics, expensive valuation, flat financial trends, and only mild technical support. A thorough evaluation of these factors is essential for making informed investment decisions in this microcap NBFC stock.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →